Rossella Siligato, G. Gembillo, E. Di Simone, Alessio Di Maria, Simone Nicoletti, L. Scichilone, Matteo Capone, Francesca Maria Vinci, M. Bondanelli, Cristina Malaventura, A. Storari, Domenico Santoro, M. Di Muzio, S. Dionisi, Fabio Fabbian
{"title":"Financial Toxicity in Renal Patients (FINTORE) Study: A Cross-Sectional Italian Study on Financial Burden in Kidney Disease-A Project Protocol.","authors":"Rossella Siligato, G. Gembillo, E. Di Simone, Alessio Di Maria, Simone Nicoletti, L. Scichilone, Matteo Capone, Francesca Maria Vinci, M. Bondanelli, Cristina Malaventura, A. Storari, Domenico Santoro, M. Di Muzio, S. Dionisi, Fabio Fabbian","doi":"10.3390/mps7020034","DOIUrl":null,"url":null,"abstract":"Financial toxicity (FT) refers to the negative impact of health-care costs on clinical conditions. In general, social determinants of health, especially poverty, socioenvironmental stressors, and psychological factors, are increasingly recognized as important determinants of non-communicable diseases, such as chronic kidney disease (CKD), and their consequences. We aim to investigate the prevalence of FT in patients at different stages of CKD treated in our universal health-care system and from pediatric nephrology, hemodialysis, peritoneal dialysis and renal transplantation clinics. FT will be assessed with the Patient-Reported Outcome for Fighting Financial Toxicity (PROFFIT) score, which was first developed by Italian oncologists. Our local ethics committee has approved the study. Our population sample will answer the sixteen questions of the PROFFIT questionnaire, seven of which are related to the outcome and nine the determinants of FT. Data will be analyzed in the pediatric and adult populations and by group stratification. We are confident that this study will raise awareness among health-care professionals of the high risk of adverse health outcomes in patients who have both kidney disease and high levels of FT. Strategies to reduce FT should be implemented to improve the standard of care for people with kidney disease and lead to truly patient-centered care.","PeriodicalId":18715,"journal":{"name":"Methods and Protocols","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Methods and Protocols","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/mps7020034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Financial toxicity (FT) refers to the negative impact of health-care costs on clinical conditions. In general, social determinants of health, especially poverty, socioenvironmental stressors, and psychological factors, are increasingly recognized as important determinants of non-communicable diseases, such as chronic kidney disease (CKD), and their consequences. We aim to investigate the prevalence of FT in patients at different stages of CKD treated in our universal health-care system and from pediatric nephrology, hemodialysis, peritoneal dialysis and renal transplantation clinics. FT will be assessed with the Patient-Reported Outcome for Fighting Financial Toxicity (PROFFIT) score, which was first developed by Italian oncologists. Our local ethics committee has approved the study. Our population sample will answer the sixteen questions of the PROFFIT questionnaire, seven of which are related to the outcome and nine the determinants of FT. Data will be analyzed in the pediatric and adult populations and by group stratification. We are confident that this study will raise awareness among health-care professionals of the high risk of adverse health outcomes in patients who have both kidney disease and high levels of FT. Strategies to reduce FT should be implemented to improve the standard of care for people with kidney disease and lead to truly patient-centered care.
财务毒性(FT)是指医疗费用对临床状况的负面影响。一般来说,健康的社会决定因素,尤其是贫困、社会环境压力和心理因素,越来越被认为是慢性肾脏病(CKD)等非传染性疾病及其后果的重要决定因素。我们的目标是调查在我国全民医疗保健系统中接受治疗的不同阶段的慢性肾脏病患者以及来自儿科肾病、血液透析、腹膜透析和肾移植诊所的患者中 FT 的流行率。FT将通过 "患者报告抗经济毒性结果"(PROFFIT)评分进行评估,该评分由意大利肿瘤专家首次提出。我们当地的伦理委员会已经批准了这项研究。我们的样本将回答 PROFFIT 问卷中的 16 个问题,其中 7 个问题与财务毒性的结果有关,9 个问题与财务毒性的决定因素有关。我们将对儿科和成人人群的数据进行分析,并按组别进行分层。我们相信,这项研究将提高医疗保健专业人员对同时患有肾病和高 FT 水平的患者不良健康后果高风险的认识。应实施降低 FT 的策略,以提高肾病患者的护理标准,实现真正以患者为中心的护理。